The antiviral activity of 9-β-D-arabinofuranosyladenine is enhanced by the 2′,3′-dideoxyriboside, the 2′,3′-didehydro-2′,3′-dideoxyriboside and the 3′-azido-2′,3′-dideoxyriboside of 2,6-diaminopurine

Add time:07/25/2019    Source:sciencedirect.com

The 2′,3′-dideoxyriboside (ddDAPR), 2′,3′-didehydro-2′,3′-dideoxyriboside (ddeDAPR) and 3′-azido-2′,3′-dideoxyriboside (AzddDAPR) of 2,6-diaminopurine have been previously recognized as potent inhibitors of human immunodeficiency virus replication. These compounds are also potent inhibitors of adenosine deaminase and inhibit the deamination of 9-β-D-arabinofuranosyladenine (araA). ddDAPR, ddeDAPR and AzddDAPR markedly potentiate the antiviral activity of araA against herpes simplex virus type 1 (HSV-1), type 2 (HSV-2) and vaccinia virus (VV). When used at a concentration of 20 μg/ml, which had by itself no antiviral effect, ddDAPR, ddeDAPR and AzddDAPR increased the ability of araA to suppress HSV-1, HSV-2 and VV yield by several orders of magnitude. The maximum antiviral effect was obtained with the combinations of ddDAPR or ddeDAPR with araA concentrations of 1 and 10 μg/ml.

We also recommend Trading Suppliers and Manufacturers of 2,6-diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside (cas 109881-25-6). Pls Click Website Link as below: cas 109881-25-6 suppliers

Prev:Pyrazoles containing thiophene, thienopyrimidine and thienotriazolopyrimidine as COX-2 selective inhibitors: Design, synthesis, in vivo anti-inflammatory activity, docking and in silico chemo-informatic studies
Next:The 2′,3′-dideoxyriboside of 2,6-diaminopurine and its 2′,3′-didehydro derivative inhibit the deamination of 2′,3′-dideoxyadenosine, an inhibitor of human immunodeficiency virus (HIV) replication)